APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL
Shionogi is acquiring IntraBio for $2B. Ono stuck inlicensing deal with Biohaven. Hanmi’s obesity drug got approval in Korea. CSL terminates supply...
86 Views
Hanmi Pharm (128940 KS/Buy)Roche’s Answer to Eli Lilly and Novo Nordisk
Our target price for Hanmi Pharm is based on an operating value estimate of W5.2tr and a pipeline value estimate of W4.3tr (vs. W3.1tr previously).
87 Views
Hanmi Pharm (128940 KS): Why Shares Plunge Despite Record High 2Q Operating Profit; What Lies Ahead
Hanmi Pharm outlicenses HM1732, next-generation muscle mass preserving obesity drug candidate with first-in-class potential, to Genentech for a...
121 Views
Hanmi Pharm (128940 KS/Buy)Focus on Beijing Hanmi’s Recovery and Pipeline Progress
Focus on Beijing Hanmi’s recovery and pipeline progressMaintain Buy; lower TP to W640,000 (from W700,000) Our target price for Hanmi Pharm is...
100 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
872 Views